Senestech, Inc. (NASDAQ:SNES) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Friday.

According to Zacks, “SenesTech, Inc. developed technology for managing animal pest populations through fertility control as opposed to a lethal approach. The Company’s fertility control product candidate, ContraPest(R), will be marketed for use initially in controlling rat infestations. SenesTech, Inc. is based in Flagstaff, Arizona. “

Shares of Senestech (NASDAQ SNES) traded down 12.86% on Friday, hitting $1.83. The stock had a trading volume of 118,608 shares. Senestech has a 52-week low of $1.83 and a 52-week high of $10.69. The firm’s 50-day moving average price is $2.05 and its 200 day moving average price is $4.83. The firm’s market cap is $18.89 million.

Senestech (NASDAQ:SNES) last announced its earnings results on Thursday, August 10th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.07). The company had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.10 million. On average, equities research analysts predict that Senestech will post ($1.30) EPS for the current year.

ILLEGAL ACTIVITY WARNING: This piece of content was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of US & international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/09/16/senestech-inc-snes-downgraded-by-zacks-investment-research.html.

In related news, Director Grover T. Wickersham acquired 15,000 shares of the firm’s stock in a transaction on Tuesday, July 25th. The stock was bought at an average cost of $2.85 per share, with a total value of $42,750.00. Following the transaction, the director now owns 238,600 shares of the company’s stock, valued at $680,010. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Andrew Altman acquired 20,000 shares of the firm’s stock in a transaction on Friday, August 18th. The shares were bought at an average cost of $2.77 per share, with a total value of $55,400.00. Following the completion of the transaction, the chief operating officer now directly owns 2,600 shares in the company, valued at approximately $7,202. The disclosure for this purchase can be found here. Over the last ninety days, insiders have acquired 54,100 shares of company stock valued at $155,730 and have sold 13,411 shares valued at $35,333. 27.40% of the stock is currently owned by company insiders.

An institutional investor recently bought a new position in Senestech stock. White Pine Capital LLC acquired a new position in shares of Senestech, Inc. (NASDAQ:SNES) in the second quarter, according to its most recent disclosure with the SEC. The firm acquired 19,250 shares of the company’s stock, valued at approximately $110,000. White Pine Capital LLC owned 0.19% of Senestech at the end of the most recent quarter. 15.34% of the stock is owned by institutional investors and hedge funds.

Senestech Company Profile

SenesTech, Inc is a United States-based biotechnology platform and research company. The Company is engaged in developing a technology for managing animal populations by fertility control. It offers ContraPest, a fertility control product candidate. ContraPest’s technology and approach targets the reproductive capabilities of both sexes.

Get a free copy of the Zacks research report on Senestech (SNES)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Senestech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senestech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.